The drug regulator for the European Union has stated that its longer approval process for COVID-19 vaccines is safer, Reuters news agency reported on Wednesday.
Emergency authorisation of Pfizer and BioNTech's COID-19 vaccine has been granted by the UK regulator.
Reuters quoted the European Medicines Agency as saying: "EMA considers that the conditional marketing authorisation is the most appropriate regulatory mechanism for use in the current pandemic emergency."
It added that procedure was based on more evidence and more checks than the emergency procedure chosen by the UK.
EMA has said that it will decide on authorisation of Pfizer's vaccine by 29 December 2020.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval